3SBio Expands Portfolio With Renal Failure Drug Acquisition
HONG KONG – 3SBio Inc. has acquired the patents for a new drug to treat renal failure from the Shanghai Institute of Materia Medica (SIMM) as part of its efforts to expand its offerings linked to diseases of the kidney.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
For Sales Inquiries,
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry
NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
http://ip-science.thomsonreuters.com/support/#open_a_support_case
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.